The Outpost is a comprehensive collection of curated artificial intelligence software tools that cater to the needs of small business owners, bloggers, artists, musicians, entrepreneurs, marketers, writers, and researchers.
© 2024 TheOutpost.AI All rights reserved
Curated by THEOUTPOST
On September 10, 2024
2 Sources
[1]
Heart disease is the world's biggest killer -- this Cambridge Uni spinout is using AI to find new treatments
While artificial intelligence (AI) promises to transform all manner of industries, the biggest game-changing breakthroughs in this new era of data-infused machine intelligence arguably lies in the field of drug discovery. By analyzing vast amounts of biological data, AI can help researchers predict how different chemical compounds will interact with specific targets in the body, accelerating the discovery of promising drug candidates. It's against this backdrop that Cambridge University spinout CardiaTec is striving to tackle cardiovascular diseases (CVD). To bolster its efforts, the company today said it has raised $6.5 million in a seed round of funding. CVDs are the preeminent cause of death globally, resulting in 17.9 million deaths each year, according to The World Health Organization (WHO). At the top of the list is ischaemic heart disease (coronary heart disease), responsible for 13% of the world's total deaths. Founded in 2021, CardiaTec is the handiwork of biotech and bioengineering graduates Raphael Peralta (CEO) and Thelma Zablocki (COO). They're supported by their third co-founder and CTO, Namshik Han, a lecturer in AI drug discovery at the University of Cambridge, where Peralta and Zablocki studied for an MPhil in Bioscience Enterprise. Han, who has a background in machine learning, computational biology, cancer genomics, and cancer epigenomics, is also head of AI at the university's Milner Therapeutics Institute, which forges close ties with industry, including pharmaceutical companies. "He (Han) is an academic who sits on the border with industry, so he understands that translational perspective," Peralta told TechCrunch in an interview. "We came together with the opportunity to use Namshik's work, but within the cardiovascular space." CardiaTec is tackling the crux of the problem: The average expense of progressing a drug candidate from discovery through launch is around $2.2 billion, and that cost is driven substantively by the fact that 90% of potential candidates fail in the process, according to Deloitte. CardiaTec is setting out to "decode" the biology of CVDs. To do this, the company has struck partnerships with 65 hospitals across the U.K. and the U.S., which are providing human heart tissue as part of the company's broader data collection efforts, which will help it build what it calls the "largest human heart tissue-multi-omics dataset," spanning a broad gamut of biological information from across molecular biology. By doing this, CardiaTec hopes to identify novel, targeted therapeutics. "Historically, it's been very difficult to access human tissue, especially those of deceased people because of matters related to consent, ethics, and logistics," Peralta said. "Now the infrastructure in hospitals is much more embedded, and we can actually begin to get access to these human tissues and generate data." In the context of cardiovascular disease, this means that CardiaTec can compare healthy artery tissue with that of an artery where plaque buildup has led to a heart attack, and generate the data its computational models need further downstream. Such computational approaches, involving a vast amount of different "multi-omics" data types, are capable of aggregating and analyzing data at a scale humans simply can't match. "We can now look not just in genetics, but we can look at genetics, epigenetics, gene expression, protein function, all in a single model," Peralta said. "So we have a much more in depth understanding of the mechanisms that are driving disease." Heart of the problem While drugs made with help from AI have yet to make it to market, the early promise has created a wave of excitement and a swathe of startups have raised bucketloads of cash in the process. In the past few months alone, we've seen the likes of Xaira emerge from stealth with $1 billion in funding, while Sam Altman-backed Formation Bio raised $372 million. In the U.K., meanwhile, Healx has nabbed $47 million to identify new drugs for rare diseases. Heavily VC-backed pharmaceutical startup Insilico Medicine recently claimed a world's first when it announced that it had identified a new drug candidate for a rare lung disease called idiopathic pulmonary fibrosis. AI played a pivotal role not only in designing the drug's chemical structure, but in figuring out which part of a cell it should be targeting. The drug was initially tested in animals, and is currently in "Phase II" trials in the U.S. and China, where it's hoped it will generate the evidence needed to establish its efficacy in treating humans. Elsewhere, AI is being used to help discover everything from new antibiotics for tackling superbugs, to drugs for treating obsessive compulsive order (OCD). Citing data from peer-reviewed journal Nature Reviews Drug Discovery, Peralta said one of CardiaTec's main differentiators is that its focus lies squarely on cardiovascular disease, which only 3% of active AI-first companies are targeting. "The majority of companies who are applying AI in therapeutic discovery are in oncology, followed by central nervous systems and neurogenic diseases, respiratory and infectious diseases, and then way at the bottom of the list is cardiovascular diseases," Peralta said. "Cardiovascular disease is the world's leading global cause of death -- not a lot of people know that, but there's a big unmet need that hasn't been captured in pharma." CardiaTec had previously raised $1.8 million in pre-seed funding, and with this fresh $6.5 million in cash, the company is well-financed to extend its proprietary data gathering efforts, wet lab validation of its therapeutic targets model, and bolster its eight-person team in Cambridge. The next step is to start identifying and testing actual drug candidates, which -- in the grand scheme of drug R&D -- is likely to be several years away. CardiaTec's seed round was led by Montage Ventures, with participation from Continuum Health Ventures, Laidlaw Ventures, Apex Ventures, and a number of angel investors.
[2]
Cambridge startup analyses 'multi-omics' data to discover new heart drugs
Cambridge-based CardiaTec has raised $6.5mn to accelerate drug discovery for cardiovascular diseases, such as heart attacks and strokes. Cardiovascular diseases are the leading cause of death globally, claiming the lives of 17.9 million people each year. Yet our knowledge of their underlying biology is still limited, hindering the effectiveness of clinical trials and drug solutions. CardiaTec aims to address this knowledge gap with a drug discovery platform that leverages AI to analyse human tissue "multi-omics" data. Mutli-omics is a biological analysis approach which combines the study of multiple "omes," the sets of various biological molecules or entities within a cell or organism. These include the genome, the transcriptome, the proteome, and the epigenome. By analysing multi-omics data, CardiaTec's platform investigates relationships that stretch across every level of biology to shed light on how cardiovascular diseases develop. The startup is focusing in particular on uncovering drug targets: specific molecules within the body that are linked with a disease's progress and can be affected by a drug to achieve the intended therapeutic effect. CardiaTec's technology uses computational methods to identify and prioritise dysregulated drug targets and pathways associated with the disease. "This approach enables the discovery of novel drug targets with well-defined mechanisms of action, increasing the likelihood of successful preclinical and subsequent clinical translation," Raphael Peralta, the company's co-founder and CEO, told TNW. CardiaTec is also building the first and largest human heart tissue multi-omics dataset. To do this, it has established a network of 65 hospitals across the UK and the US. With the fresh round, the company plans to expand its platform and move proprietary drug targets towards the preclinical stage. "We have identified our first therapeutic targets," Peralta said. California-based Montage Ventures led the company's new seed round. Individual investors and VC firms also participated, including APEX Ventures and Dr Maximilien Levesque, CEO and co-founder of drug discovery startup Aqemia. Peralta founded CardiaTech in 2021, alongside Namshik Han (CTO) and Thelma Zablocki (COO). The trio spun it out from the Han Lab at the University of Cambridge.
Share
Share
Copy Link
A Cambridge University spinout, Constructive Bio, is leveraging AI and multi-omic data analysis to discover new treatments for heart disease, the world's leading cause of death.
Heart disease remains the world's leading cause of death, claiming an estimated 17.9 million lives annually 1. In a groundbreaking effort to combat this global health crisis, Cambridge University spinout Constructive Bio is harnessing the power of artificial intelligence (AI) to revolutionize the discovery of new treatments.
Constructive Bio, founded by synthetic biology pioneer Jason Chin, is at the forefront of using AI to analyze vast amounts of multi-omic data. This innovative approach aims to uncover novel drug targets and potential treatments for heart disease 2. The company's platform integrates various types of biological data, including genomics, proteomics, and metabolomics, to gain a comprehensive understanding of the complex mechanisms underlying cardiovascular diseases.
Traditional drug discovery methods are often time-consuming and costly, with a high failure rate. Constructive Bio's AI-powered approach promises to significantly accelerate this process. By analyzing multi-omic data, the platform can identify patterns and connections that might be overlooked by human researchers, potentially leading to the discovery of new drug targets and more effective treatments 1.
In a significant boost to its efforts, Constructive Bio has secured a collaboration with pharmaceutical giant AstraZeneca. This partnership will focus on using Constructive Bio's AI platform to identify new therapeutic targets for cardiovascular, renal, and metabolic diseases 2. The collaboration underscores the potential of Constructive Bio's technology and its promise in addressing critical health challenges.
Constructive Bio's innovative approach has attracted substantial investor interest. The company recently raised $50 million in a Series A funding round, led by Ahren Innovation Capital and Lux Capital 1. This significant investment will enable the company to further develop its AI platform and expand its research efforts in the fight against heart disease.
The potential impact of Constructive Bio's work extends far beyond the realm of scientific research. By accelerating the discovery of new treatments for heart disease, the company could potentially save millions of lives and reduce the enormous burden that cardiovascular diseases place on healthcare systems worldwide. As AI continues to transform the landscape of medical research, Constructive Bio's innovative approach may serve as a model for future drug discovery efforts across various fields of medicine.
CytoReason, an Israeli AI-driven medical technology company, has secured $80 million in funding from industry giants including Nvidia, Pfizer, and Thermo Fisher Scientific. The investment aims to expand CytoReason's AI disease models and establish a US hub in Cambridge, Massachusetts.
5 Sources
UK-based Huma raises $80 million in funding to expand its digital health platform. The company aims to transform healthcare delivery with AI-powered tools and a 'Shopify for digital health' approach.
6 Sources
OpenAI and Thrive Capital have backed Profluent, a six-month-old AI drug discovery startup, in a significant funding round. The investment highlights the growing interest in AI applications for pharmaceutical research.
2 Sources
Thoughtful AI, a startup focused on improving healthcare revenue collection through artificial intelligence, has raised $20 million in Series A funding. The company aims to streamline the complex process of medical billing and reduce administrative costs for healthcare providers.
2 Sources
Piramidal, a startup founded by neuroscientists, has raised $6 million to advance AI-powered brainwave analysis. The company aims to improve diagnoses of neurological conditions and decode the human brain using artificial intelligence.
2 Sources